title: Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion.
abstract: At low doses, dobutamine has potent inotropic, but limited chronotropic, effects-properties that may be necessary for detection of hibernating myocardium. The efficacy of other catecholamines, which have more closely coupled inotropic and chronotropic effects, for the detection of viable myocardium is unknown. This study evaluated the efficacy of arbutamine, a catecholamine with potent chrono-tropic effects, for the detection of viable myocardium in a canine model of hibernating myocardium. Contractile reserve was assessed during stepwise arbutamine infusion (dosages of 2.5, 5, 10, 50, and 100 ng/kg/min) at 3 days (early) and 4 weeks (late) after coronary ligation. Segment shortening, wall thickening, and segmental wall motion were assessed by sonomicrometry and echocardiography. After 4 weeks of occlusion, functional recovery was assessed after revascularization. During the early arbutamine study, the sensitivity for predicting functional recovery was highest at a dosage of 50 ng/kg/min, which also produced tachycardia. The sensitivity was 50% for segment shortening, 20% for wall thickening, and 75% for wall motion score. The late arbutamine study had improved sensitivity. The sensitivity was 100% for segment shortening, 80% for wall thickening, and 90% for wall motion score at a dosage of 50 ng/kg/min. At the late arbutamine study, myocardial perfusion reserve in the ischemic zone of dogs with functional recovery was only mildly reduced (2.0 versus 2.6 in nonischemic zones, P =.53). After coronary occlusion, viable myocardium can be detected with high doses of arbutamine that produce tachycardia. However, the sensitivity of arbutamine stimulation for predicting functional recovery is low early after occlusion, but it is improved by 4 weeks after occlusion with adequate perfusion reserve.
authors.affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
authors.forename: A
authors.initials: A
authors.lastname: Kisanuki
authors.forename: D S
authors.initials: DS
authors.lastname: Segar
authors.forename: T
authors.initials: T
authors.lastname: Ryan
authors.forename: M
authors.initials: M
authors.lastname: Johnson
authors.forename: C
authors.initials: C
authors.lastname: Tei
authors.forename: H
authors.initials: H
authors.lastname: Feigenbaum
authors.forename: S G
authors.initials: SG
authors.lastname: Sawada
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents; D002395:Catecholamines; D002908:Chronic Disease; D004195:Disease Models, Animal; D004285:Dogs; D006439:Hemodynamics; D009200:Myocardial Contraction / Q000187:drug effects; D017682:Myocardial Stunning / Q000175:diagnosis* / Q000000981:diagnostic imaging; D012039:Regional Blood Flow; D012680:Sensitivity and Specificity; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis
chemical_list: D002316:Cardiotonic Agents; D002395:Catecholamines; C076559:arbutamine